ADAR1 Capital Management »

Fulcrum Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Fulcrum Therapeutics (FULC) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Fulcrum Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Fulcrum Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Fulcrum Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $3.2M 340k 9.44
2023-12-31 $4.3M 637k 6.75

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Fulcrum Therapeutics

RA Capital Management
BlackRock
BlackRock
Nantahala Capital Management
Caption Management
Vanguard Group
Suvretta Capital Management
Trv Gp Iv
Citadel Advisors
Perceptive Advisors
Logos Global Management
MPM Oncology Impact Management
Leucadia National Corporation
Dimensional Fund Advisors
Geode Capital Management

View all funds holding Fulcrum Therapeutics